159 filings
Page 5 of 8
8-K
3lkpjpyja5ytwm
7 Aug 20
Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
4:43pm
8-K
ofrtd4qs1ge7ovc2dakc
6 Aug 20
Entry into a Material Definitive Agreement
8:51am
8-K
59bi 7sw6he
8 Jun 20
Submission of Matters to a Vote of Security Holders
4:46pm
8-K
ds2llh 4as91
7 May 20
Denali Therapeutics Reports First Quarter 2020 Financial Results and Provides COVID-19 Response Update
12:00am
DEFA14A
kvsrrn d5wl9e2
22 Apr 20
Additional proxy soliciting materials
4:38pm
8-K
cpw05gce35y867l4d4
2 Apr 20
Denali Therapeutics Provides Pipeline and Business Update In Response to the COVID-19 Pandemic
4:34pm
S-8
t4ob343uvljlfaq
28 Feb 20
Registration of securities for employees
12:00am
8-K
gbhfhc1vzk5to 1qo8
27 Feb 20
Denali Therapeutics Reports Full Year 2019 Financial Results and Business Highlights
5:17pm
8-K
ymzs5aye7zoef6ouy
29 Jan 20
Denali Therapeutics Announces Pricing of Public Offering of Common Stock
4:25pm
424B5
q7a6s7lmdrtt29t0snl
29 Jan 20
Prospectus supplement for primary offering
4:24pm
8-K
h8vinbva8ue
27 Jan 20
Denali Therapeutics Announces Proposed Offering of Common Stock
5:13pm
424B5
eo33qnd
27 Jan 20
Prospectus supplement for primary offering
5:12pm
8-K
lr6fhhcl4ise3
14 Jan 20
Denali Therapeutics Announces Broad Pipeline Progress Including Positive Results from Its LRRK2 Program for Parkinson’s Disease
9:04am
8-K
523m5y qd
6 Nov 19
Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights
4:32pm
UPLOAD
8dshc bsk2mx75fn2sg7
7 Oct 19
Letter from SEC
12:00am
CORRESP
welupothk297pc pv90
11 Sep 19
Correspondence with SEC
12:00am